Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 326

1.

Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.

Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L, Abdul-Ghani M.

Diabetes Care. 2016 Aug 25. pii: dc152688. [Epub ahead of print]

PMID:
27561923
2.

SGLT2 Inhibitors: Benefit/Risk Balance.

Scheen AJ.

Curr Diab Rep. 2016 Oct;16(10):92. doi: 10.1007/s11892-016-0789-4. Review.

PMID:
27541294
3.

ABCC8-Related Maturity-Onset Diabetes of the Young (MODY12): Clinical Features and Treatment Perspective.

Ovsyannikova AK, Rymar OD, Shakhtshneider EV, Klimontov VV, Koroleva EA, Myakina NE, Voevoda MI.

Diabetes Ther. 2016 Aug 18. [Epub ahead of print]

PMID:
27538677
5.

Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.

Madaan T, Akhtar M, Najmi AK.

Eur J Pharm Sci. 2016 Aug 12;93:244-252. doi: 10.1016/j.ejps.2016.08.025. [Epub ahead of print] Review.

PMID:
27531551
6.

Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.

Vakkalagadda B, Lubin S, Reynolds L, Liang D, Marion AS, LaCreta F, Boulton DW.

Clin Ther. 2016 Aug;38(8):1890-9. doi: 10.1016/j.clinthera.2016.07.005. Epub 2016 Aug 2.

PMID:
27491280
7.

Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.

Monami M, Dicembrini I, Mannucci E.

Acta Diabetol. 2016 Aug 4. [Epub ahead of print]

PMID:
27488726
8.

The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.

Candelario N, Wykretowicz J.

Oxf Med Case Reports. 2016 Jul 27;2016(7):144-6. doi: 10.1093/omcr/omw061. eCollection 2016 Jul.

9.

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes: Cardiovascular and Kidney Effects, Potential Mechanisms and Clinical Applications.

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.

Circulation. 2016 Jul 28. pii: CIRCULATIONAHA.116.021887. [Epub ahead of print]

PMID:
27470878
10.

Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.

Mellander A, Billger M, Johnsson E, Träff AK, Yoshida S, Johnsson K.

Clin Drug Investig. 2016 Jul 26. [Epub ahead of print]

PMID:
27461213
11.

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2016 Jul 29:1-11. [Epub ahead of print]

PMID:
27435042
12.

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.

Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E.

J Pharmacol Sci. 2016 Jul;131(3):198-208. doi: 10.1016/j.jphs.2016.06.004. Epub 2016 Jun 29.

13.

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.

Singh JS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, Pearson ER, Struthers AD, Lang CC.

Cardiovasc Diabetol. 2016 Jul 15;15:97. doi: 10.1186/s12933-016-0419-0.

14.

Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets.

LaCreta F, Griffen SC, Liu X, Smith C, Hines C, Volk K, Tejwani R, Boulton DW.

Int J Pharm. 2016 Sep 10;511(1):288-95. doi: 10.1016/j.ijpharm.2016.07.017. Epub 2016 Jul 12.

PMID:
27418571
15.

▼ Empagliflozin, diabetes and outcomes.

[No authors listed]

Drug Ther Bull. 2016 Jul;54(7):78-81. doi: 10.1136/dtb.2016.6.0411.

PMID:
27417322
16.

Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.

Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, Song YQ.

Diabetes Obes Metab. 2016 Jul 13. doi: 10.1111/dom.12742. [Epub ahead of print]

PMID:
27407013
17.

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.

Chang YK, Choi H, Jeong JY, Na KR, Lee KW, Lim BJ, Choi DE.

PLoS One. 2016 Jul 8;11(7):e0158810. doi: 10.1371/journal.pone.0158810. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0160478.

18.

Pharmacological aspects of the safety of gliflozins.

Faillie JL.

Pharmacol Res. 2016 Jul 5. pii: S1043-6618(16)30636-3. doi: 10.1016/j.phrs.2016.07.001. [Epub ahead of print] Review.

PMID:
27389050
19.

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Davies M, Chatterjee S, Khunti K.

Clin Pharmacol. 2016 Jun 23;8:61-81. doi: 10.2147/CPAA.S82008. eCollection 2016. Review.

20.

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.

Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, Day EA, Salt IP, Steinberg GR, Hardie DG.

Diabetes. 2016 Sep;65(9):2784-94. doi: 10.2337/db16-0058. Epub 2016 Jul 5.

PMID:
27381369
Items per page

Supplemental Content

Loading ...
Write to the Help Desk